This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feng, Y. Articles by Dimitrov, D. S. Search for Related Content PubMed PubMed Citation Articles by Feng, Y. Articles by Dimitrov, D. S.

¹ Protein Interactions Group, Nanobiology Program, Center for Cancer Research; ² Basic Research Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, NIH, Frederick, Maryland; and ³ Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Dimiter S. Dimitrov, Nanobiology Program, Center for Cancer Research, National Cancer Institute-Frederick, Room 105, NIH Building 469, Frederick, MD 21702-1201. Phone: 301-846-1352; Fax: 301-846-5598. E-mail: dimitrov{at}ncifcrf.gov

The insulin-like growth factor (IGF) system plays an important role in a variety of physiologic processes and in diseases such as cancer. Although the role of the IGF system in cancer has been recognized many years ago, components of the system have only recently been targeted and shown to affect cell transformation, proliferation, survival, motility, and migration in tissue cultures and in mouse models of cancer. We have been hypothesizing that targeting IGF-II in addition to blocking its interaction with the IGF receptor type I (IGF-IR) would also allow to block that portion of the signal transduction through the insulin receptor that is due to its interaction with IGF-II. Lowering its level may also not induce up-regulation of its production as for IGF-I. Finally, targeting a diffusable ligand as IGF-II may not require penetration of the antibody inside tumors but could shift the equilibrium to IGF-II complexed with antibody so the ligand concentration would decrease in the tumor environment without the need for the antibody to penetrate the tumor. Here, we describe the identification and characterization of three novel anti-IGF-II fully human monoclonal antibodies. They bound with high (subnanomolar) affinity to IGF-II, did not cross-react with IGF-I and insulin, and potently inhibited signal transduction mediated by the IGF-IR interaction with IGF-II. The most potent neutralizer, IgG1 m610, inhibited phosphorylation of the IGF-IR and the insulin receptor, as well as phosphorylation of the downstream kinases Akt and mitogen-activated protein kinase with an IC₅₀ of the order of 1 nmol/L at IGF-II concentration of 10 nmol/L. It also inhibited growth of the prostate cancer cell line DU145 and migration of the breast cancer line cells MCF-7. These results indicate an immunotherapeutic potential of IgG1 m610 likely in combination with other antibodies and anticancer drugs but only further experiments in mouse models of cancer and human clinical trials could evaluate this possibility. [Mol Cancer Ther 2006;5(1):114–20]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: J.C. Barrett is currently at Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Ave., Suite 3A250, Cambridge, MA 02139.

⁴ Z. Zhu and D.S. Dimitrov, manuscript in preparation.

Received 7/18/05; revised 10/11/05; accepted 10/25/05.

This article has been cited by other articles:

				S. N. Prince, E. J. Foulstone, O. J. Zaccheo, C. Williams, and A. B. Hassan Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor Mol. Cancer Ther., February 1, 2007; 6(2): 607 - 617. [Abstract] [Full Text] [PDF]